Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Inotuzumab Ozogamicin

It is intended for the treatment of adults with acute lymphoblastic leukaemia
26 Apr 2017
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 21 April 2017, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the medicinal product inotuzumab ozogamicin (Besponsa), intended for the treatment of adults with acute lymphoblastic leukaemia. Besponsa was designated as an orphan medicinal product on 7 June 2013.

The applicant for this medicinal product is Pfizer Limited.

Besponsa will be available as a 1-mg powder for concentrate for solution for infusion. The active substance of Besponsa is inotuzumab ozogamicin, a humanised immunoglobulin class G subtype 4 (IgG4) antibody (ATC code: L01XC26) that specifically recognises human CD22.

Besponsa has been shown to increase the proportion of patients who have complete remission and molecular remission and to delay the progression of disease.

The most common side effects are thrombocytopenia, neutropenia, anaemia, leucopenia, infection, haemorrhage and venoocclusive liver disease/sinusoidal obstruction syndrome.

The full indication is: "Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI)".

It is proposed that Besponsa be prescribed by physicians experienced in treating cancer.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Last update: 26 Apr 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.